Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
about
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyOncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans."Special exemptions": should they be put on trial?
P2860
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
@en
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
@nl
type
label
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
@en
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
@nl
prefLabel
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
@en
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
@nl
P2860
P356
P1433
P1476
Treatment of chemotherapy-refractory cancer in the advanced therapy access program.
@en
P2860
P304
P356
10.1038/MT.2012.170
P577
2012-09-01T00:00:00Z